Amid the shortage of ADHD medications, the FDA has approved several generic versions of Vyvanse for the treatment of attention-deficit/hyperactivity disorder in people 6 years and older.
"The FDA made the review and approval of these generics a priority, and hopefully manufacturing will now scale up rapidly to meet this pressing need," he told Fox News Digital.
The FDA has approved several generic versions of Vyvanse for the treatment of attention-deficit/hyperactivity disorder in people 6 years and older. Potential side effects are likely the same as with the brand-name drug, he noted, though some may experience different side effects on the generic version.Lisdexamfetamine is used in the treatment of attention deficit hyperactivity disorder and binge-eating disorder.
The cost of the generic Vyvanse should be considerably less than the brand-name ADHD drugs, Herman said.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Enter Our September Sweepstakes: 'What Your ADHD Child Wishes You Knew'Enter to win one of five copies of 'What Your ADHD Child Wishes You Knew' — a parenting blueprint by ADDitude contributor Sharon Saline, Psy.D. — by answering this question in the Comments: What do you wish the world knew about your ADHD child or your ADHD brain?
Read more »
FDA must close flavored vape loopholeThe FDA’s regulation of vaping has been too lenient. Illegally marketed and unregulated e-cigarette products evade legal frameworks and pose additional health...
Read more »
ICU Medical Gets FDA Clearance for Infusion Pump-Software ComboBy Dean Seal ICU Medical has received clearance from the U.S. Food and Drug Administration for its Plum Duo infusion pump with LifeShield infusion safety...
Read more »
FDA approves RSV vaccine in pregnancy to protect infantsFederal regulators approved a maternal RSV vaccine on Aug. 21 that would be administered during pregnancy to protect infants from severe illness.
Read more »
FDA to Step Up Oversight of Cosmetics, Assess PFASA 2022 law expanded the FDA's authority to regulate makeup, and it also set a 3-year deadline for a report on potential risk of PFAS, known as 'forever chemicals,' in cosmetics.
Read more »